Global Targeted Protein Degradation Market

Targeted Protein Degradation Comprehensive Study by Type (Degronimids, IMiDs, PROTACs, SARDs, SERDs, Specific BET & DUB Inhibitors), Application (Healthcare), Therapeutic Area (Inflammatory Disorders, Neurological Disorders, Oncological Disorders, Respiratory Disorders, Other Therapeutic Areas), Route (Oral, Intravenous, Others) Players and Region - Global Market Outlook to 2027

Targeted Protein Degradation Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Targeted Protein Degradation
Over the past decades, continuous progress has been made towards understanding the bifunctional molecules(Physiochemical and biological properties), variety of other chemical entities and molecular glues have been developed for the treatment of a variety of clinical including, Alzheimer’s disease, breast cancer, psoriasis and many more, by enabling efficient hit discovery and characterization of potential therapeutics leads. Targeted Protein Degradation is stating to the use of heterobifunctional small molecule l degraders used to achieve knockdown of target proteins within cells, it consists of binding moieties for an E3 ubiquitin ligase and a target protein joined by a linker. In addition, it represents an exciting new therapeutic opportunity to eliminate disease-causing proteins. Substantial advancements have been made in the discovery and development of clinically relevant degraders is booming the importance of targeted protein degradation in the market.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Targeted Protein Degradation market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

5AM Venture (United States),, AbbVie Inc (United States), Almac Group (United Kingdom), Amgen Inc. (United States), Bayer AG (Germany), Biogen Inc. (United States), C4 Therapeutics (United States), Cosmo Bio USA (United States), Eli Lilly and Company (United States), Mission Therapeutics (United States) and Roivant Sciences (Switzerland) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Targeted Protein Degradation market by Type (Degronimids, IMiDs, PROTACs, SARDs, SERDs and Specific BET & DUB Inhibitors), Application (Healthcare) and Region.



On the basis of geography, the market of Targeted Protein Degradation has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Therapeutic Area, the sub-segment i.e. Inflammatory Disorders will boost the Targeted Protein Degradation market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route, the sub-segment i.e. Oral will boost the Targeted Protein Degradation market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
On 26th April 2021, Evotec announced that Bristol Myers Squibb has exercised its option to extend its 2018 strategic drug discovery and development partnership in the field of targeted protein degradation. The collaboration employs Evotec’s PanOmics platform, which combines throughput proteomics, high throughput transcriptomics, and cell imaging with PanHunter, a data analysis platform
ON 22nd April 2021, PerkinElmer, Inc. announced that it is serving as a provider and co-developer of assays, instrument solutions, and expertise for the PROXIDRUGS Consortium which is zeroing in on research for proximity drugs or PROTACs (PROteolysis Targeting Chimeras). and On 6th December 2020, Roivant Sciences unveiled its targeted protein degradation platform which includes novel degraders for multiple diseases across oncology, immunology, and neurology.


Market Drivers
  • The Growing Awareness Among The People Regarding The Benefits Of Protein Degradation Which Will Help In Boosting The Growth Of The Market
  • Increasing Demand for Protein Degradation for Drug Discovery Strategy to Treat Diseases Which Will Likely to Enhance The Growth Of The Targeted Protein Degradation

Opportunities
  • The Growing Popularity And Interest In The Therapeutic Potential Of These Molecules Is Evident Across Modern Scientific Literature And Adoption Of These Therapeutics And Affiliated Technologies, Over The Next Decades
  • The Technological Advancement And Developing Protein Degraders Research Want To Break Into That Ubiquitin-Proteasome Machinery To Change The Purpose Of Disease-Causing Proteins Is Booming The Opportunities Of Growth In The Market

Restraints
  • High Protease Susceptibly and Low Cell Permeability will Likely to Hamper the Growth

Challenges
  • Complex Structure and the Interactions between the E3 Ligase and The Target Protein


Key Target Audience
Government associations, Research organizations, Targeted Protein Degradation vendors and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • Degronimids
  • IMiDs
  • PROTACs
  • SARDs
  • SERDs
  • Specific BET & DUB Inhibitors
By Application
  • Healthcare
By Therapeutic Area
  • Inflammatory Disorders
  • Neurological Disorders
  • Oncological Disorders
  • Respiratory Disorders
  • Other Therapeutic Areas

By Route
  • Oral
  • Intravenous
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Growing Awareness Among The People Regarding The Benefits Of Protein Degradation Which Will Help In Boosting The Growth Of The Market
      • 3.2.2. Increasing Demand for Protein Degradation for Drug Discovery Strategy to Treat Diseases Which Will Likely to Enhance The Growth Of The Targeted Protein Degradation
    • 3.3. Market Challenges
      • 3.3.1. Complex Structure and the Interactions between the E3 Ligase and The Target Protein
    • 3.4. Market Trends
      • 3.4.1. Increasing Usages Of Technology For Epichaperome Inhibitors, Hydrophobic Tags, Lysosome Targeting Chimeras, And Others
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Targeted Protein Degradation, by Type, Application, Therapeutic Area, Route and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Targeted Protein Degradation (Value)
      • 5.2.1. Global Targeted Protein Degradation by: Type (Value)
        • 5.2.1.1. Degronimids
        • 5.2.1.2. IMiDs
        • 5.2.1.3. PROTACs
        • 5.2.1.4. SARDs
        • 5.2.1.5. SERDs
        • 5.2.1.6. Specific BET & DUB Inhibitors
      • 5.2.2. Global Targeted Protein Degradation by: Application (Value)
        • 5.2.2.1. Healthcare
      • 5.2.3. Global Targeted Protein Degradation by: Therapeutic Area (Value)
        • 5.2.3.1. Inflammatory Disorders
        • 5.2.3.2. Neurological Disorders
        • 5.2.3.3. Oncological Disorders
        • 5.2.3.4. Respiratory Disorders
        • 5.2.3.5. Other Therapeutic Areas
      • 5.2.4. Global Targeted Protein Degradation by: Route (Value)
        • 5.2.4.1. Oral
        • 5.2.4.2. Intravenous
        • 5.2.4.3. Others
      • 5.2.5. Global Targeted Protein Degradation Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Targeted Protein Degradation (Volume)
      • 5.3.1. Global Targeted Protein Degradation by: Type (Volume)
        • 5.3.1.1. Degronimids
        • 5.3.1.2. IMiDs
        • 5.3.1.3. PROTACs
        • 5.3.1.4. SARDs
        • 5.3.1.5. SERDs
        • 5.3.1.6. Specific BET & DUB Inhibitors
      • 5.3.2. Global Targeted Protein Degradation by: Application (Volume)
        • 5.3.2.1. Healthcare
      • 5.3.3. Global Targeted Protein Degradation by: Therapeutic Area (Volume)
        • 5.3.3.1. Inflammatory Disorders
        • 5.3.3.2. Neurological Disorders
        • 5.3.3.3. Oncological Disorders
        • 5.3.3.4. Respiratory Disorders
        • 5.3.3.5. Other Therapeutic Areas
      • 5.3.4. Global Targeted Protein Degradation by: Route (Volume)
        • 5.3.4.1. Oral
        • 5.3.4.2. Intravenous
        • 5.3.4.3. Others
      • 5.3.5. Global Targeted Protein Degradation Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Targeted Protein Degradation (Price)
      • 5.4.1. Global Targeted Protein Degradation by: Type (Price)
  • 6. Targeted Protein Degradation: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. 5AM Venture (United States),
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AbbVie Inc (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Almac Group (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Amgen Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Biogen Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. C4 Therapeutics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cosmo Bio USA (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eli Lilly and Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mission Therapeutics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Roivant Sciences (Switzerland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Targeted Protein Degradation Sale, by Type, Application, Therapeutic Area, Route and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Targeted Protein Degradation (Value)
      • 7.2.1. Global Targeted Protein Degradation by: Type (Value)
        • 7.2.1.1. Degronimids
        • 7.2.1.2. IMiDs
        • 7.2.1.3. PROTACs
        • 7.2.1.4. SARDs
        • 7.2.1.5. SERDs
        • 7.2.1.6. Specific BET & DUB Inhibitors
      • 7.2.2. Global Targeted Protein Degradation by: Application (Value)
        • 7.2.2.1. Healthcare
      • 7.2.3. Global Targeted Protein Degradation by: Therapeutic Area (Value)
        • 7.2.3.1. Inflammatory Disorders
        • 7.2.3.2. Neurological Disorders
        • 7.2.3.3. Oncological Disorders
        • 7.2.3.4. Respiratory Disorders
        • 7.2.3.5. Other Therapeutic Areas
      • 7.2.4. Global Targeted Protein Degradation by: Route (Value)
        • 7.2.4.1. Oral
        • 7.2.4.2. Intravenous
        • 7.2.4.3. Others
      • 7.2.5. Global Targeted Protein Degradation Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Targeted Protein Degradation (Volume)
      • 7.3.1. Global Targeted Protein Degradation by: Type (Volume)
        • 7.3.1.1. Degronimids
        • 7.3.1.2. IMiDs
        • 7.3.1.3. PROTACs
        • 7.3.1.4. SARDs
        • 7.3.1.5. SERDs
        • 7.3.1.6. Specific BET & DUB Inhibitors
      • 7.3.2. Global Targeted Protein Degradation by: Application (Volume)
        • 7.3.2.1. Healthcare
      • 7.3.3. Global Targeted Protein Degradation by: Therapeutic Area (Volume)
        • 7.3.3.1. Inflammatory Disorders
        • 7.3.3.2. Neurological Disorders
        • 7.3.3.3. Oncological Disorders
        • 7.3.3.4. Respiratory Disorders
        • 7.3.3.5. Other Therapeutic Areas
      • 7.3.4. Global Targeted Protein Degradation by: Route (Volume)
        • 7.3.4.1. Oral
        • 7.3.4.2. Intravenous
        • 7.3.4.3. Others
      • 7.3.5. Global Targeted Protein Degradation Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Targeted Protein Degradation (Price)
      • 7.4.1. Global Targeted Protein Degradation by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Targeted Protein Degradation: by Type(USD Million)
  • Table 2. Targeted Protein Degradation Degronimids , by Region USD Million (2016-2021)
  • Table 3. Targeted Protein Degradation IMiDs , by Region USD Million (2016-2021)
  • Table 4. Targeted Protein Degradation PROTACs , by Region USD Million (2016-2021)
  • Table 5. Targeted Protein Degradation SARDs , by Region USD Million (2016-2021)
  • Table 6. Targeted Protein Degradation SERDs , by Region USD Million (2016-2021)
  • Table 7. Targeted Protein Degradation Specific BET & DUB Inhibitors , by Region USD Million (2016-2021)
  • Table 8. Targeted Protein Degradation: by Application(USD Million)
  • Table 9. Targeted Protein Degradation Healthcare , by Region USD Million (2016-2021)
  • Table 10. Targeted Protein Degradation: by Therapeutic Area(USD Million)
  • Table 11. Targeted Protein Degradation Inflammatory Disorders , by Region USD Million (2016-2021)
  • Table 12. Targeted Protein Degradation Neurological Disorders , by Region USD Million (2016-2021)
  • Table 13. Targeted Protein Degradation Oncological Disorders , by Region USD Million (2016-2021)
  • Table 14. Targeted Protein Degradation Respiratory Disorders , by Region USD Million (2016-2021)
  • Table 15. Targeted Protein Degradation Other Therapeutic Areas , by Region USD Million (2016-2021)
  • Table 16. Targeted Protein Degradation: by Route(USD Million)
  • Table 17. Targeted Protein Degradation Oral , by Region USD Million (2016-2021)
  • Table 18. Targeted Protein Degradation Intravenous , by Region USD Million (2016-2021)
  • Table 19. Targeted Protein Degradation Others , by Region USD Million (2016-2021)
  • Table 20. South America Targeted Protein Degradation, by Country USD Million (2016-2021)
  • Table 21. South America Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 22. South America Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 23. South America Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 24. South America Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 25. Brazil Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 26. Brazil Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 27. Brazil Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 28. Brazil Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 29. Argentina Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 30. Argentina Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 31. Argentina Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 32. Argentina Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 33. Rest of South America Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 34. Rest of South America Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 35. Rest of South America Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 36. Rest of South America Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 37. Asia Pacific Targeted Protein Degradation, by Country USD Million (2016-2021)
  • Table 38. Asia Pacific Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 39. Asia Pacific Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 40. Asia Pacific Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 41. Asia Pacific Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 42. China Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 43. China Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 44. China Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 45. China Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 46. Japan Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 47. Japan Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 48. Japan Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 49. Japan Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 50. India Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 51. India Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 52. India Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 53. India Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 54. South Korea Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 55. South Korea Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 56. South Korea Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 57. South Korea Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 58. Taiwan Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 59. Taiwan Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 60. Taiwan Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 61. Taiwan Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 62. Australia Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 63. Australia Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 64. Australia Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 65. Australia Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 66. Rest of Asia-Pacific Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 67. Rest of Asia-Pacific Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 68. Rest of Asia-Pacific Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 69. Rest of Asia-Pacific Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 70. Europe Targeted Protein Degradation, by Country USD Million (2016-2021)
  • Table 71. Europe Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 72. Europe Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 73. Europe Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 74. Europe Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 75. Germany Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 76. Germany Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 77. Germany Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 78. Germany Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 79. France Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 80. France Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 81. France Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 82. France Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 83. Italy Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 84. Italy Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 85. Italy Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 86. Italy Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 87. United Kingdom Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 88. United Kingdom Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 89. United Kingdom Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 90. United Kingdom Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 91. Netherlands Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 92. Netherlands Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 93. Netherlands Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 94. Netherlands Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 95. Rest of Europe Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 96. Rest of Europe Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 97. Rest of Europe Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 98. Rest of Europe Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 99. MEA Targeted Protein Degradation, by Country USD Million (2016-2021)
  • Table 100. MEA Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 101. MEA Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 102. MEA Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 103. MEA Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 104. Middle East Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 105. Middle East Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 106. Middle East Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 107. Middle East Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 108. Africa Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 109. Africa Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 110. Africa Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 111. Africa Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 112. North America Targeted Protein Degradation, by Country USD Million (2016-2021)
  • Table 113. North America Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 114. North America Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 115. North America Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 116. North America Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 117. United States Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 118. United States Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 119. United States Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 120. United States Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 121. Canada Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 122. Canada Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 123. Canada Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 124. Canada Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 125. Mexico Targeted Protein Degradation, by Type USD Million (2016-2021)
  • Table 126. Mexico Targeted Protein Degradation, by Application USD Million (2016-2021)
  • Table 127. Mexico Targeted Protein Degradation, by Therapeutic Area USD Million (2016-2021)
  • Table 128. Mexico Targeted Protein Degradation, by Route USD Million (2016-2021)
  • Table 129. Targeted Protein Degradation Sales: by Type(K Units)
  • Table 130. Targeted Protein Degradation Sales Degronimids , by Region K Units (2016-2021)
  • Table 131. Targeted Protein Degradation Sales IMiDs , by Region K Units (2016-2021)
  • Table 132. Targeted Protein Degradation Sales PROTACs , by Region K Units (2016-2021)
  • Table 133. Targeted Protein Degradation Sales SARDs , by Region K Units (2016-2021)
  • Table 134. Targeted Protein Degradation Sales SERDs , by Region K Units (2016-2021)
  • Table 135. Targeted Protein Degradation Sales Specific BET & DUB Inhibitors , by Region K Units (2016-2021)
  • Table 136. Targeted Protein Degradation Sales: by Application(K Units)
  • Table 137. Targeted Protein Degradation Sales Healthcare , by Region K Units (2016-2021)
  • Table 138. Targeted Protein Degradation Sales: by Therapeutic Area(K Units)
  • Table 139. Targeted Protein Degradation Sales Inflammatory Disorders , by Region K Units (2016-2021)
  • Table 140. Targeted Protein Degradation Sales Neurological Disorders , by Region K Units (2016-2021)
  • Table 141. Targeted Protein Degradation Sales Oncological Disorders , by Region K Units (2016-2021)
  • Table 142. Targeted Protein Degradation Sales Respiratory Disorders , by Region K Units (2016-2021)
  • Table 143. Targeted Protein Degradation Sales Other Therapeutic Areas , by Region K Units (2016-2021)
  • Table 144. Targeted Protein Degradation Sales: by Route(K Units)
  • Table 145. Targeted Protein Degradation Sales Oral , by Region K Units (2016-2021)
  • Table 146. Targeted Protein Degradation Sales Intravenous , by Region K Units (2016-2021)
  • Table 147. Targeted Protein Degradation Sales Others , by Region K Units (2016-2021)
  • Table 148. South America Targeted Protein Degradation Sales, by Country K Units (2016-2021)
  • Table 149. South America Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 150. South America Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 151. South America Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 152. South America Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 153. Brazil Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 154. Brazil Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 155. Brazil Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 156. Brazil Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 157. Argentina Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 158. Argentina Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 159. Argentina Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 160. Argentina Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 161. Rest of South America Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 162. Rest of South America Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 163. Rest of South America Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 164. Rest of South America Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 165. Asia Pacific Targeted Protein Degradation Sales, by Country K Units (2016-2021)
  • Table 166. Asia Pacific Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 167. Asia Pacific Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 168. Asia Pacific Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 169. Asia Pacific Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 170. China Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 171. China Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 172. China Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 173. China Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 174. Japan Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 175. Japan Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 176. Japan Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 177. Japan Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 178. India Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 179. India Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 180. India Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 181. India Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 182. South Korea Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 183. South Korea Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 184. South Korea Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 185. South Korea Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 186. Taiwan Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 187. Taiwan Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 188. Taiwan Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 189. Taiwan Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 190. Australia Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 191. Australia Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 192. Australia Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 193. Australia Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 194. Rest of Asia-Pacific Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 195. Rest of Asia-Pacific Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 196. Rest of Asia-Pacific Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 197. Rest of Asia-Pacific Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 198. Europe Targeted Protein Degradation Sales, by Country K Units (2016-2021)
  • Table 199. Europe Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 200. Europe Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 201. Europe Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 202. Europe Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 203. Germany Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 204. Germany Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 205. Germany Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 206. Germany Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 207. France Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 208. France Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 209. France Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 210. France Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 211. Italy Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 212. Italy Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 213. Italy Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 214. Italy Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 215. United Kingdom Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 216. United Kingdom Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 217. United Kingdom Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 218. United Kingdom Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 219. Netherlands Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 220. Netherlands Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 221. Netherlands Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 222. Netherlands Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 223. Rest of Europe Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 224. Rest of Europe Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 225. Rest of Europe Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 226. Rest of Europe Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 227. MEA Targeted Protein Degradation Sales, by Country K Units (2016-2021)
  • Table 228. MEA Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 229. MEA Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 230. MEA Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 231. MEA Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 232. Middle East Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 233. Middle East Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 234. Middle East Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 235. Middle East Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 236. Africa Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 237. Africa Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 238. Africa Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 239. Africa Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 240. North America Targeted Protein Degradation Sales, by Country K Units (2016-2021)
  • Table 241. North America Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 242. North America Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 243. North America Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 244. North America Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 245. United States Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 246. United States Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 247. United States Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 248. United States Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 249. Canada Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 250. Canada Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 251. Canada Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 252. Canada Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 253. Mexico Targeted Protein Degradation Sales, by Type K Units (2016-2021)
  • Table 254. Mexico Targeted Protein Degradation Sales, by Application K Units (2016-2021)
  • Table 255. Mexico Targeted Protein Degradation Sales, by Therapeutic Area K Units (2016-2021)
  • Table 256. Mexico Targeted Protein Degradation Sales, by Route K Units (2016-2021)
  • Table 257. Targeted Protein Degradation: by Type(USD/Units)
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Targeted Protein Degradation: by Type(USD Million)
  • Table 270. Targeted Protein Degradation Degronimids , by Region USD Million (2022-2027)
  • Table 271. Targeted Protein Degradation IMiDs , by Region USD Million (2022-2027)
  • Table 272. Targeted Protein Degradation PROTACs , by Region USD Million (2022-2027)
  • Table 273. Targeted Protein Degradation SARDs , by Region USD Million (2022-2027)
  • Table 274. Targeted Protein Degradation SERDs , by Region USD Million (2022-2027)
  • Table 275. Targeted Protein Degradation Specific BET & DUB Inhibitors , by Region USD Million (2022-2027)
  • Table 276. Targeted Protein Degradation: by Application(USD Million)
  • Table 277. Targeted Protein Degradation Healthcare , by Region USD Million (2022-2027)
  • Table 278. Targeted Protein Degradation: by Therapeutic Area(USD Million)
  • Table 279. Targeted Protein Degradation Inflammatory Disorders , by Region USD Million (2022-2027)
  • Table 280. Targeted Protein Degradation Neurological Disorders , by Region USD Million (2022-2027)
  • Table 281. Targeted Protein Degradation Oncological Disorders , by Region USD Million (2022-2027)
  • Table 282. Targeted Protein Degradation Respiratory Disorders , by Region USD Million (2022-2027)
  • Table 283. Targeted Protein Degradation Other Therapeutic Areas , by Region USD Million (2022-2027)
  • Table 284. Targeted Protein Degradation: by Route(USD Million)
  • Table 285. Targeted Protein Degradation Oral , by Region USD Million (2022-2027)
  • Table 286. Targeted Protein Degradation Intravenous , by Region USD Million (2022-2027)
  • Table 287. Targeted Protein Degradation Others , by Region USD Million (2022-2027)
  • Table 288. South America Targeted Protein Degradation, by Country USD Million (2022-2027)
  • Table 289. South America Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 290. South America Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 291. South America Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 292. South America Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 293. Brazil Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 294. Brazil Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 295. Brazil Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 296. Brazil Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 297. Argentina Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 298. Argentina Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 299. Argentina Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 300. Argentina Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 301. Rest of South America Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 302. Rest of South America Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 303. Rest of South America Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 304. Rest of South America Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 305. Asia Pacific Targeted Protein Degradation, by Country USD Million (2022-2027)
  • Table 306. Asia Pacific Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 307. Asia Pacific Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 308. Asia Pacific Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 309. Asia Pacific Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 310. China Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 311. China Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 312. China Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 313. China Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 314. Japan Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 315. Japan Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 316. Japan Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 317. Japan Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 318. India Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 319. India Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 320. India Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 321. India Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 322. South Korea Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 323. South Korea Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 324. South Korea Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 325. South Korea Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 326. Taiwan Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 327. Taiwan Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 328. Taiwan Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 329. Taiwan Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 330. Australia Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 331. Australia Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 332. Australia Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 333. Australia Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 334. Rest of Asia-Pacific Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 335. Rest of Asia-Pacific Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 336. Rest of Asia-Pacific Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 337. Rest of Asia-Pacific Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 338. Europe Targeted Protein Degradation, by Country USD Million (2022-2027)
  • Table 339. Europe Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 340. Europe Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 341. Europe Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 342. Europe Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 343. Germany Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 344. Germany Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 345. Germany Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 346. Germany Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 347. France Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 348. France Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 349. France Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 350. France Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 351. Italy Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 352. Italy Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 353. Italy Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 354. Italy Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 355. United Kingdom Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 356. United Kingdom Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 357. United Kingdom Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 358. United Kingdom Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 359. Netherlands Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 360. Netherlands Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 361. Netherlands Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 362. Netherlands Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 363. Rest of Europe Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 364. Rest of Europe Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 365. Rest of Europe Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 366. Rest of Europe Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 367. MEA Targeted Protein Degradation, by Country USD Million (2022-2027)
  • Table 368. MEA Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 369. MEA Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 370. MEA Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 371. MEA Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 372. Middle East Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 373. Middle East Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 374. Middle East Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 375. Middle East Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 376. Africa Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 377. Africa Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 378. Africa Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 379. Africa Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 380. North America Targeted Protein Degradation, by Country USD Million (2022-2027)
  • Table 381. North America Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 382. North America Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 383. North America Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 384. North America Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 385. United States Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 386. United States Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 387. United States Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 388. United States Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 389. Canada Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 390. Canada Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 391. Canada Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 392. Canada Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 393. Mexico Targeted Protein Degradation, by Type USD Million (2022-2027)
  • Table 394. Mexico Targeted Protein Degradation, by Application USD Million (2022-2027)
  • Table 395. Mexico Targeted Protein Degradation, by Therapeutic Area USD Million (2022-2027)
  • Table 396. Mexico Targeted Protein Degradation, by Route USD Million (2022-2027)
  • Table 397. Targeted Protein Degradation Sales: by Type(K Units)
  • Table 398. Targeted Protein Degradation Sales Degronimids , by Region K Units (2022-2027)
  • Table 399. Targeted Protein Degradation Sales IMiDs , by Region K Units (2022-2027)
  • Table 400. Targeted Protein Degradation Sales PROTACs , by Region K Units (2022-2027)
  • Table 401. Targeted Protein Degradation Sales SARDs , by Region K Units (2022-2027)
  • Table 402. Targeted Protein Degradation Sales SERDs , by Region K Units (2022-2027)
  • Table 403. Targeted Protein Degradation Sales Specific BET & DUB Inhibitors , by Region K Units (2022-2027)
  • Table 404. Targeted Protein Degradation Sales: by Application(K Units)
  • Table 405. Targeted Protein Degradation Sales Healthcare , by Region K Units (2022-2027)
  • Table 406. Targeted Protein Degradation Sales: by Therapeutic Area(K Units)
  • Table 407. Targeted Protein Degradation Sales Inflammatory Disorders , by Region K Units (2022-2027)
  • Table 408. Targeted Protein Degradation Sales Neurological Disorders , by Region K Units (2022-2027)
  • Table 409. Targeted Protein Degradation Sales Oncological Disorders , by Region K Units (2022-2027)
  • Table 410. Targeted Protein Degradation Sales Respiratory Disorders , by Region K Units (2022-2027)
  • Table 411. Targeted Protein Degradation Sales Other Therapeutic Areas , by Region K Units (2022-2027)
  • Table 412. Targeted Protein Degradation Sales: by Route(K Units)
  • Table 413. Targeted Protein Degradation Sales Oral , by Region K Units (2022-2027)
  • Table 414. Targeted Protein Degradation Sales Intravenous , by Region K Units (2022-2027)
  • Table 415. Targeted Protein Degradation Sales Others , by Region K Units (2022-2027)
  • Table 416. South America Targeted Protein Degradation Sales, by Country K Units (2022-2027)
  • Table 417. South America Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 418. South America Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 419. South America Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 420. South America Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 421. Brazil Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 422. Brazil Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 423. Brazil Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 424. Brazil Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 425. Argentina Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 426. Argentina Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 427. Argentina Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 428. Argentina Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 429. Rest of South America Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 430. Rest of South America Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 431. Rest of South America Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 432. Rest of South America Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 433. Asia Pacific Targeted Protein Degradation Sales, by Country K Units (2022-2027)
  • Table 434. Asia Pacific Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 435. Asia Pacific Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 436. Asia Pacific Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 437. Asia Pacific Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 438. China Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 439. China Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 440. China Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 441. China Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 442. Japan Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 443. Japan Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 444. Japan Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 445. Japan Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 446. India Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 447. India Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 448. India Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 449. India Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 450. South Korea Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 451. South Korea Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 452. South Korea Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 453. South Korea Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 454. Taiwan Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 455. Taiwan Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 456. Taiwan Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 457. Taiwan Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 458. Australia Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 459. Australia Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 460. Australia Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 461. Australia Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 462. Rest of Asia-Pacific Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 463. Rest of Asia-Pacific Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 464. Rest of Asia-Pacific Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 465. Rest of Asia-Pacific Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 466. Europe Targeted Protein Degradation Sales, by Country K Units (2022-2027)
  • Table 467. Europe Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 468. Europe Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 469. Europe Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 470. Europe Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 471. Germany Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 472. Germany Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 473. Germany Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 474. Germany Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 475. France Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 476. France Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 477. France Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 478. France Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 479. Italy Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 480. Italy Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 481. Italy Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 482. Italy Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 483. United Kingdom Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 484. United Kingdom Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 485. United Kingdom Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 486. United Kingdom Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 487. Netherlands Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 488. Netherlands Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 489. Netherlands Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 490. Netherlands Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 491. Rest of Europe Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 492. Rest of Europe Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 493. Rest of Europe Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 494. Rest of Europe Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 495. MEA Targeted Protein Degradation Sales, by Country K Units (2022-2027)
  • Table 496. MEA Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 497. MEA Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 498. MEA Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 499. MEA Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 500. Middle East Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 501. Middle East Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 502. Middle East Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 503. Middle East Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 504. Africa Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 505. Africa Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 506. Africa Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 507. Africa Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 508. North America Targeted Protein Degradation Sales, by Country K Units (2022-2027)
  • Table 509. North America Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 510. North America Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 511. North America Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 512. North America Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 513. United States Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 514. United States Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 515. United States Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 516. United States Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 517. Canada Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 518. Canada Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 519. Canada Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 520. Canada Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 521. Mexico Targeted Protein Degradation Sales, by Type K Units (2022-2027)
  • Table 522. Mexico Targeted Protein Degradation Sales, by Application K Units (2022-2027)
  • Table 523. Mexico Targeted Protein Degradation Sales, by Therapeutic Area K Units (2022-2027)
  • Table 524. Mexico Targeted Protein Degradation Sales, by Route K Units (2022-2027)
  • Table 525. Targeted Protein Degradation: by Type(USD/Units)
  • Table 526. Research Programs/Design for This Report
  • Table 527. Key Data Information from Secondary Sources
  • Table 528. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Targeted Protein Degradation: by Type USD Million (2016-2021)
  • Figure 5. Global Targeted Protein Degradation: by Application USD Million (2016-2021)
  • Figure 6. Global Targeted Protein Degradation: by Therapeutic Area USD Million (2016-2021)
  • Figure 7. Global Targeted Protein Degradation: by Route USD Million (2016-2021)
  • Figure 8. South America Targeted Protein Degradation Share (%), by Country
  • Figure 9. Asia Pacific Targeted Protein Degradation Share (%), by Country
  • Figure 10. Europe Targeted Protein Degradation Share (%), by Country
  • Figure 11. MEA Targeted Protein Degradation Share (%), by Country
  • Figure 12. North America Targeted Protein Degradation Share (%), by Country
  • Figure 13. Global Targeted Protein Degradation: by Type K Units (2016-2021)
  • Figure 14. Global Targeted Protein Degradation: by Application K Units (2016-2021)
  • Figure 15. Global Targeted Protein Degradation: by Therapeutic Area K Units (2016-2021)
  • Figure 16. Global Targeted Protein Degradation: by Route K Units (2016-2021)
  • Figure 17. South America Targeted Protein Degradation Share (%), by Country
  • Figure 18. Asia Pacific Targeted Protein Degradation Share (%), by Country
  • Figure 19. Europe Targeted Protein Degradation Share (%), by Country
  • Figure 20. MEA Targeted Protein Degradation Share (%), by Country
  • Figure 21. North America Targeted Protein Degradation Share (%), by Country
  • Figure 22. Global Targeted Protein Degradation: by Type USD/Units (2016-2021)
  • Figure 23. Global Targeted Protein Degradation share by Players 2021 (%)
  • Figure 24. Global Targeted Protein Degradation share by Players (Top 3) 2021(%)
  • Figure 25. Global Targeted Protein Degradation share by Players (Top 5) 2021(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. 5AM Venture (United States), Revenue, Net Income and Gross profit
  • Figure 28. 5AM Venture (United States), Revenue: by Geography 2021
  • Figure 29. AbbVie Inc (United States) Revenue, Net Income and Gross profit
  • Figure 30. AbbVie Inc (United States) Revenue: by Geography 2021
  • Figure 31. Almac Group (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. Almac Group (United Kingdom) Revenue: by Geography 2021
  • Figure 33. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Amgen Inc. (United States) Revenue: by Geography 2021
  • Figure 35. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Bayer AG (Germany) Revenue: by Geography 2021
  • Figure 37. Biogen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Biogen Inc. (United States) Revenue: by Geography 2021
  • Figure 39. C4 Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 40. C4 Therapeutics (United States) Revenue: by Geography 2021
  • Figure 41. Cosmo Bio USA (United States) Revenue, Net Income and Gross profit
  • Figure 42. Cosmo Bio USA (United States) Revenue: by Geography 2021
  • Figure 43. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 44. Eli Lilly and Company (United States) Revenue: by Geography 2021
  • Figure 45. Mission Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 46. Mission Therapeutics (United States) Revenue: by Geography 2021
  • Figure 47. Roivant Sciences (Switzerland) Revenue, Net Income and Gross profit
  • Figure 48. Roivant Sciences (Switzerland) Revenue: by Geography 2021
  • Figure 49. Global Targeted Protein Degradation: by Type USD Million (2022-2027)
  • Figure 50. Global Targeted Protein Degradation: by Application USD Million (2022-2027)
  • Figure 51. Global Targeted Protein Degradation: by Therapeutic Area USD Million (2022-2027)
  • Figure 52. Global Targeted Protein Degradation: by Route USD Million (2022-2027)
  • Figure 53. South America Targeted Protein Degradation Share (%), by Country
  • Figure 54. Asia Pacific Targeted Protein Degradation Share (%), by Country
  • Figure 55. Europe Targeted Protein Degradation Share (%), by Country
  • Figure 56. MEA Targeted Protein Degradation Share (%), by Country
  • Figure 57. North America Targeted Protein Degradation Share (%), by Country
  • Figure 58. Global Targeted Protein Degradation: by Type K Units (2022-2027)
  • Figure 59. Global Targeted Protein Degradation: by Application K Units (2022-2027)
  • Figure 60. Global Targeted Protein Degradation: by Therapeutic Area K Units (2022-2027)
  • Figure 61. Global Targeted Protein Degradation: by Route K Units (2022-2027)
  • Figure 62. South America Targeted Protein Degradation Share (%), by Country
  • Figure 63. Asia Pacific Targeted Protein Degradation Share (%), by Country
  • Figure 64. Europe Targeted Protein Degradation Share (%), by Country
  • Figure 65. MEA Targeted Protein Degradation Share (%), by Country
  • Figure 66. North America Targeted Protein Degradation Share (%), by Country
  • Figure 67. Global Targeted Protein Degradation: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • 5AM Venture (United States),
  • AbbVie Inc (United States)
  • Almac Group (United Kingdom)
  • Amgen Inc. (United States)
  • Bayer AG (Germany)
  • Biogen Inc. (United States)
  • C4 Therapeutics (United States)
  • Cosmo Bio USA (United States)
  • Eli Lilly and Company (United States)
  • Mission Therapeutics (United States)
  • Roivant Sciences (Switzerland)
Select User Access Type

Key Highlights of Report


Jul 2022 167 Pages 54 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Targeted Protein Degradation Market Quantitative research analysis
Global Targeted Protein Degradation Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as 5AM Venture (United States),, AbbVie Inc (United States), Almac Group (United Kingdom), Amgen Inc. (United States), Bayer AG (Germany), Biogen Inc. (United States), C4 Therapeutics (United States), Cosmo Bio USA (United States), Eli Lilly and Company (United States), Mission Therapeutics (United States) and Roivant Sciences (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Usages Of Technology For Epichaperome Inhibitors, Hydrophobic Tags, Lysosome Targeting Chimeras, And Others" is seen as one of major influencing trends for Targeted Protein Degradation Market during projected period 2021-2027.
The Targeted Protein Degradation market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Targeted Protein Degradation Market Report?

Have a Query? Click Here

Other Related Reports

Biosimilar Testing Service Comprehensive Study by Type (Pharmacokinetic Assay, Tiered Immunogenicity Testing, NAb Assays), Application (Pharmaceutical and Biopharmaceutical Companies, Contract resear...
$ 3800
Ophthalmic Data Management Systems Comprehensive Study by Deployment Mode (Cloud-Based, Web-Based), Disease Type (Glaucoma, Diabetic Retinopathy, Refractive Error, Age-Related Macular Degeneration, A...
$ 3750
Weight Loss and Diet Management Comprehensive Study by Application (Child, Teen Weight Management, Adult Weight Management, Geriatric Weight Management), Diet Type (Paleo Diet, Low Carb, Keto Diet,...
$ 3800
Orthopedic Procedures Comprehensive Study by Application (Hip, Knee, Spine, Dental, Shoulder, Others), Procedure (Arthroscopy, Joint Reconstruction, Soft Tissue Replacement, Spinal Surgery Procedure,...
$ 3450
Chronic Care Management Solution Comprehensive Study by Type (Medical Reference/Education, Chronic Disease Management, Care Coordination, Others.), Deployment Mode (Cloud-based, On-premise), End-user...
$ 3450
Endocrine Peptides Test Comprehensive Study by Type (Estradiol (E2), Dehydroepiandrosterone sulfate (DHEAS), Human Chorionic Gonadotropin (hCG), Progesterone, Luteinizing Hormone (LH), Thyroid Stimul...
$ 3750